Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03873714 · ClinicalTrials.gov registry record · NA
Pipeline™ Vantage Embolization Device With Shield Technology™ for Wide-Necked Intracranial Aneurysms (ADVANCE)
A NA study, sponsored by Medtronic Neurovascular Clinical Affairs.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT03873714 is a NA study that was terminated before completion, run by Medtronic Neurovascular Clinical Affairs. The registered enrollment target is 14 participants.
The verdict
NCT03873714, a NA study, was terminated before completion, sponsored by Medtronic Neurovascular Clinical Affairs.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of the Pipeline™ Vantage Embolization Device with Shield Technology™ in the treatment of intracranial aneurysms within the intended indication for use.
Interventions
- DEVICE Pipeline™ Vantage Embolization Device with Shield Technology™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-04-02 |
| Est. Completion | 2023-09-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03873714
The ClinicalTrials.gov registry entry for NCT03873714 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Neurovascular Clinical Affairs, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pipeline™ Vantage Embolization Device with Shield Technology™ is the first listed.
NCT03873714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03873714 about?
NCT03873714 is a clinical study titled "Pipeline™ Vantage Embolization Device With Shield Technology™ for Wide-Necked Intracranial Aneurysms (ADVANCE)". The purpose of this study is to assess the safety and effectiveness of the Pipeline™ Vantage Embolization Device with Shield Technology™ in the treatment of intracranial aneurysms within the intended indication for use.
What is the current status of trial NCT03873714?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2020-04-02. Estimated completion is 2023-09-18.
What interventions are being tested in trial NCT03873714?
The interventions under investigation include: Pipeline™ Vantage Embolization Device with Shield Technology™ (DEVICE).
Who is sponsoring clinical trial NCT03873714?
This trial is sponsored by Medtronic Neurovascular Clinical Affairs, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.